Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

• Published in: Science translational medicine Vol. 6; no. 228; p. 228ra39
• Main Authors: Yates, Nicole L, Liao, Hua-Xin, Fong, Youyi, deCamp, Allan, Vandergrift, Nathan A, Williams, William T, Alam, S Munir, Ferrari, Guido, Yang, Zhi-yong, Seaton, Kelly E, Berman, Phillip W, Alpert, Michael D, Evans, David T, O'Connell, Robert J, Francis, Donald, Sinangil, Faruk, Lee, Carter, Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Kaewkungwal, Jaranit, Pitisuttithum, Punnee, Tartaglia, James, Pinter, Abraham, Zolla-Pazner, Susan, Gilbert, Peter B, Nabel, Gary J, Michael, Nelson L, Kim, Jerome H, Montefiori, David C, Haynes, Barton F, Tomaras, Georgia D
• Format: Journal Article
• Language: English
• Published: United States 19.03.2014
• Subjects: AIDS Vaccines - administration & dosage; AIDS Vaccines - immunology; HIV Antibodies - biosynthesis; HIV Antibodies - immunology; HIV Infections - immunology; HIV Infections - prevention & control; HIV-1; Humans; Immunoglobulin G - immunology
• ISSN: 1946-6242
• DOI: 10.1126/scitranslmed.3007730

HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.